颅内Castleman病一例

2020-03-14 陈正 梁文 莫森林 临床放射学杂志

患者女,32岁。于2017年1月初无明显诱因出现头痛,为发作性胀痛不适,3~5min自行缓解,无头晕、呕吐、行走不稳、肢体无力、肢体麻木、口角抽搐、意识不清、听力下降、视物模糊。

患者女,32岁。于2017年1月初无明显诱因出现头痛,为发作性胀痛不适,3~5min自行缓解,无头晕、呕吐、行走不稳、肢体无力、肢体麻木、口角抽搐、意识不清、听力下降、视物模糊。

MRI表现:T1WI呈等信号,T2WI呈中等偏高信号,DWI呈稍弥散受限,增强扫描呈明显强化,与脑组织以线样低信号影分界,与硬脑膜呈宽基底相连,其脑膜尾粗、长;右侧颞、顶叶大脑受压,皮质向内凹陷,右侧颞、枕、顶叶见大片状水肿带,右侧侧脑室后角受压,中线稍向左偏移。

CT表现:右侧颞顶部见一规则高密度影,与硬脑膜宽基底相连,边界清楚,平扫CT值约50HU,增强扫描明显强化,CT值约110HU,邻近颅骨骨质结构破坏吸收,周围见明显水肿带(图1~8)。


图1T1WI呈中等稍高信号;图2T2WI呈等信号;图3DWI表现为弥散稍受限;图4增强扫描轴位,强化明显;图5增强扫描冠状位,可见明显脑膜尾征;图6CT平扫表现为高密度影;图7CT增强扫描明显强化;图8CT骨窗可见骨质破坏吸收;

术中见脑内肿瘤突出脑组织表面,张力较高,与周围水肿带分界不清,肿瘤向前、向下沿硬脑膜弥漫生长。术后病理提示:右侧颞顶叶符合巨淋巴结增生(Castleman病),镜下见(右侧颞顶)淋巴组织增生,淋巴滤泡大小不等,滤泡中央可见硬化血管,滤泡周围可见呈同心圆排列的淋巴细胞,血管内皮增生,较多浆细胞和组织细胞浸润。免疫组织化学示:Vim(+),淋巴细胞Bcl-2(+),CD3(+),CD20(+),浆细胞CD38(+),CD138散在(+),组织细胞CD68(+),S-100(-),CD34(-),GFAP(-),EMA(-),PR(-),Ki-67约40%(+)(图9)。


图9可见淋巴滤泡增生,滤泡中央可见硬化血管,滤泡周围可见呈同心圆排列的淋巴细胞,血管内皮增生(HE×200)

讨论

巨淋巴结增生症是一种少见良性增生性疾病,病因不明,据文献报道可能与血管内皮因子、EB病毒感染、HHV-8感染及细胞因子调节异常有关,现更多学者认为其发生与HHV-8感染及白细胞介素-6增多有关,1956年由Castleman等首先报道此病。巨淋巴结增生症根据病理学特点将其分为三型:透明血管型(主要由增生的淋巴结及丰富的血管构成)、浆细胞型(主要由滤泡及滤泡间片状成熟的浆细胞构成)和中间型(为兼有两种类型的混合体)。

临床及影像上分为:局限型与弥漫型两种类型,其中透明血管型约占本病的80%~90%,浆细胞型约占本病的3%~10%。本病可发生于任何年龄、任何存在淋巴组织的部位,其中纵隔及肺门占60%~70%,颈部占10%~14%,腹部占5%~10%,腋窝占2%~4%。由于发生于颅脑罕见,国内尚鲜有文献报道,对其影像认识不足,本病术前与脑膜瘤鉴别困难。脑膜瘤其信号及密度可不均匀,增强扫描多见较明显强化,其脑膜尾多呈细线样改变,邻近骨质以增生改变多见,对颅骨呈骨质破坏者少见,脑膜瘤MRS可出现特征性Ala峰。

颅内Castleman病非常罕见,本例与另一文献报道均出现粗、长脑膜尾征,提示当诊断为脑外肿瘤及出现明显粗、长脑膜尾征时,不能除外该病可能,加做MRS可能有助于鉴别诊断。目前颅内Castleman尚未有报道行MRS扫描,其意义有待于进一步探索。

原始出处:

陈正,梁文,莫森林.颅内Castleman病一例[J].临床放射学杂志,2019(01):182-183.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712348, encodeId=6f6d1e123483b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 21 18:15:29 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317553, encodeId=f3a8131e55322, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321629, encodeId=f38613216295c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624950, encodeId=f0c01624950c6, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712348, encodeId=6f6d1e123483b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 21 18:15:29 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317553, encodeId=f3a8131e55322, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321629, encodeId=f38613216295c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624950, encodeId=f0c01624950c6, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-03-16 fengyi812
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712348, encodeId=6f6d1e123483b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 21 18:15:29 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317553, encodeId=f3a8131e55322, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321629, encodeId=f38613216295c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624950, encodeId=f0c01624950c6, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712348, encodeId=6f6d1e123483b, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Fri Aug 21 18:15:29 CST 2020, time=2020-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317553, encodeId=f3a8131e55322, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321629, encodeId=f38613216295c, content=<a href='/topic/show?id=3fc54145ea' target=_blank style='color:#2F92EE;'>#Castleman病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4145, encryptionId=3fc54145ea, topicName=Castleman病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624950, encodeId=f0c01624950c6, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Mon Mar 16 01:15:29 CST 2020, time=2020-03-16, status=1, ipAttribution=)]
    2020-03-16 yaanren

相关资讯

Blood:李剑教授团队——全口服制剂治疗Castleman病的II期研究

近日,中国医学科学院北京协和医院血液科李剑教授团队关于全口服制剂(口服沙利度胺-环磷酰胺-泼尼松,TCP方案)治疗特发性多中心型Castleman病的II期临床研究发表在美国血液病学会官方杂志《血液》(Blood)上。这一研究为iMCD患者提供了一种经济、便捷、有效率高的治疗新选择。

首发症状为颌下腺肿大的Castleman病超声表现1例

患者男,49岁。自述双侧颌下肿大2个月余,无红肿、疼痛等不适,近一周感觉肿大明显来我院检查。有轻微盗汗,偶伴胸闷、气短及口干。查体:双侧颌下均可触及一包块,表面不光滑,无压痛。双颈部、腋下及腹股沟可触及多个淋巴结,质韧,表面光滑,无压痛,活动度尚可。

Blood:巨淋巴结增生症!

Castleman病(CD,又称巨淋巴结增生症)是一组具有组织病理特异性的异质性血液病,表现为单区域或多区域淋巴结肿大(MCD)。MCD的部分病例是由人疱疹病毒-8(HHV-8)感染引起的,而其他病例为HHV-8阴性或特发性(iMCD)。由于尚无统一的治疗指南,iMCD的治疗充满挑战性,预后可能很差;而且系统性的研究较少,也无明确的缓解标准。为提高iMCD患者预后,Castleman病协会从10个

老年男子,体检发现盆腔肿物1月....

老年男子,体检发现盆腔肿物1月....

拓展阅读

【Blood Rev】特发性多中心型Castleman病的诊断和治疗新进展

由于过去十年中实验室检查和药物治疗取得重大进展,Evan Lang和Frits van Rhee两位教授针对 iMCD 的新发展和报道进行了更新审查并撰写综述。

【协和医学杂志】白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

对罕见病患者群体的关注程度,与社会的文明进步程度密切相关。

【衡道丨笔记】从POEMS-MCD到Castleman Disease诊断体会

张磊老师分享了从POEMS-MCD到Castleman Disease诊断体会的相关内容,摘要如下。

中国Castleman病的临床特征、治疗和预后因素:一项执行 CDCN 标准的全国、多中心、回顾性研究

该研究是首次实施和评价 CDCN CD 诊断标准的同类研究,也是CD领域迄今为止世界上最大的回顾性研究,也是中国描述 IL-6 靶向治疗时代之前中国CD患者治疗模式和预后的最大研究。

Castleman病(局灶性、多中心)丨影像表现

Castleman病(局灶性、多中心)丨影像表现

Castleman病:症状与体征、病因、流行病学、诊断与治疗

Castleman 病(Castleman disease,CD),卡斯尔曼病,又称巨大淋巴结病或血管滤泡性淋巴结增生症。是一种较为少见的淋巴增生性疾病。1956 年由 Benjamin Castle